Biom Therapeutics announces positive Phase 2 topline data results for their lead drug candidate, Bio017, a groundbreaking treatment against developmental and epileptic encephalopathies (DEE).
SARASOTA, Fl. Sept. 9, 2020/PR Newswire/ — Biom Therapeutics announces today that its lead drug candidate Bio017 has shown positive topline data in phase 2 studies as a treatment against developmental and epileptic encephalopathies (DEE). Biom Therapeutics intends to initiate plans for the phase 3 SATURN randomized controlled study by early 2021, which could be completed by the end of next year.
Developmental & Epileptic Encephalopathies (DEE), a heterogeneous group of rare and ultra-rare epilepsy syndromes that manifest with seizures, behavioral disturbances, or EEG abnormalities, can directly worsen cognition and behavior. DEEs are lifelong conditions generally characterized by persistent severe seizures.
John Allen, president of Biom Therapeutics, explains, “We are extremely pleased with the topline results from our phase 2 studies by using cannabinoid (CBD) to target multiple pathologies of DEE without significant adverse effects.”
Developmental & Epileptic Encephalopathies (DEE) has a forecasted market size of $3 billion by 2030 to meet the needs of 115,000 patients in the U.S. and Europe.1,2,3 DEEs are lifelong conditions generally characterized by persistent severe seizures with concomitant cognitive, developmental, and behavioral issues.
Bobban Subhadra, the company’s chairman/CEO, stated, “Currently, there is a huge unmet need for new therapies. The goals of treatment are not only to control seizures, but also to improve neurologic functions and behavioral parameters.”
1. Delvelnsight, “Dravet& Lennox-Gastaut Syndrome – Market Insights, Epidemiology, and Market Forecast 2030,” 2020.
2. Delvelnsight, “Dup 15q Syndrome and CDKL5 Deficiency Disorder – Market Insights, Epidemiology, and Market Forecast 2030,” 2020.
3. Guggenheim Securities, LLC, “The Epilepsy Report,” November 2009.
About Biom Therapeutics
Biom Therapeutics is a clinical stage biopharmaceutical company founded by a team of business leaders, scientists, and clinicians that develops therapeutics for hard-to-treat neurological diseases. Biom Therapeutics is emerging as a world-class biotech firm that improves human health and quality of life by developing innovative drugs for treating and potentially reversing the effects of hard-to-treat diseases such as rare epilepsies, Alzheimer’s disease, and autism. The firm’s initial focus is on rare pediatric epilepsy, including developmental and epileptic encephalopathies and Angelman syndrome. Our talented team of scientists, scientific advisors, and board directors is working diligently to accelerate breakthrough treatments for patients with significant unmet medical needs.